Cargando…
A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degrader, with or without Ribociclib or Alpelisib, in Patients with Estrogen Receptor–Positive Breast Cancer
PURPOSE: Data are sparse for oral selective estrogen receptor (ER) degraders (SERD) in cancer treatment. The investigational oral SERD LSZ102 was assessed in monotherapy and combination use in a phase I study. PATIENTS AND METHODS: A phase I, multicenter, open-label dose-escalation study (NCT0273461...
Autores principales: | Jhaveri, Komal, Juric, Dejan, Yap, Yoon-Sim, Cresta, Sara, Layman, Rachel M., Duhoux, Francois P., Terret, Catherine, Takahashi, Shunji, Huober, Jens, Kundamal, Nicole, Sheng, Qing, Balbin, Alejandro, Ji, Yan, He, Wei, Crystal, Adam, De Vita, Serena, Curigliano, Giuseppe |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for Cancer Research
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9401512/ https://www.ncbi.nlm.nih.gov/pubmed/34433648 http://dx.doi.org/10.1158/1078-0432.CCR-21-1095 |
Ejemplares similares
-
Phosphatidylinositol-3 Kinase Inhibitors, Buparlisib and Alpelisib, Sensitize Estrogen Receptor-positive Breast Cancer Cells to Tamoxifen
por: Chen, I-Chun, et al.
Publicado: (2017) -
Preclinical evaluation of ribociclib and its synergistic effect in combination with alpelisib in non-keratinizing nasopharyngeal carcinoma
por: Wong, Chi-Hang, et al.
Publicado: (2018) -
An Open-label Phase I Study of GDC-0927 in Postmenopausal Women with Locally Advanced or Metastatic Estrogen Receptor–Positive Breast Cancer
por: Chandarlapaty, Sarat, et al.
Publicado: (2023) -
Phase Ib/II Trial of Ribociclib in Combination with Binimetinib in Patients with NRAS-mutant Melanoma
por: Schuler, Martin, et al.
Publicado: (2022) -
Sapanisertib plus Fulvestrant in Postmenopausal Women with Estrogen Receptor–Positive/HER2-Negative Advanced Breast Cancer after Progression on Aromatase Inhibitor
por: García-Sáenz, José Á., et al.
Publicado: (2022)